These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. Yeh MK; Liu YT; Chen JL; Chiang CH J Control Release; 2002 Aug; 82(2-3):237-47. PubMed ID: 12175740 [TBL] [Abstract][Full Text] [Related]
3. The stability of insulin in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Yeh MK J Microencapsul; 2000; 17(6):743-56. PubMed ID: 11063421 [TBL] [Abstract][Full Text] [Related]
4. Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination. Yeh M; Chiang C J Microencapsul; 2004 Feb; 21(1):91-106. PubMed ID: 14718189 [TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro characteristics for insulin-loaded PLA microparticles prepared by w/o/w solvent evaporation method with electrolytes in the continuous phase. Yeh MK; Chen JL; Chiang CH J Microencapsul; 2004 Nov; 21(7):719-28. PubMed ID: 15799222 [TBL] [Abstract][Full Text] [Related]
7. Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing. Witschi C; Doelker E J Control Release; 1998 Feb; 51(2-3):327-41. PubMed ID: 9685930 [TBL] [Abstract][Full Text] [Related]
8. The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Lavelle EC; Yeh MK; Coombes AG; Davis SS Vaccine; 1999 Feb; 17(6):512-29. PubMed ID: 10075157 [TBL] [Abstract][Full Text] [Related]
9. Formulation factors for preparing ocular biodegradable delivery system of 5-fluorouracil microparticles. Yeh MK; Tung SM; Lu DW; Chen JL; Chiang CH J Microencapsul; 2001; 18(4):507-19. PubMed ID: 11428679 [TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of poly-(D,L-lactide-co-glycolide) and poly-(L-lactic acid) microspheres with entrapped pneumotropic bacterial antigens. Kofler N; Ruedl C; Klima J; Recheis H; Böck G; Wick G; Wolf H J Immunol Methods; 1996 Jun; 192(1-2):25-35. PubMed ID: 8699019 [TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics. Bittner B; Morlock M; Koll H; Winter G; Kissel T Eur J Pharm Biopharm; 1998 May; 45(3):295-305. PubMed ID: 9653634 [TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of hCG-loaded polylactide or poly(lactide-co-glycolide) microspheres using a modified water-in-oil-in-water (w/o/w) emulsion solvent evaporation technique. Zhu KJ; Jiang HL; Du XY; Wang J; Xu WX; Liu SF J Microencapsul; 2001; 18(2):247-60. PubMed ID: 11253941 [TBL] [Abstract][Full Text] [Related]
13. A new method for preparing biodegradable microparticles and entrapment of hydrocortisone in DL-PLG microparticles using supercritical fluids. Ghaderi R; Artursson P; Carlfors J Eur J Pharm Sci; 2000 Mar; 10(1):1-9. PubMed ID: 10699378 [TBL] [Abstract][Full Text] [Related]
14. Preparation of biodegradable microparticles using solution-enhanced dispersion by supercritical fluids (SEDS). Ghaderi R; Artursson P; Carlfors J Pharm Res; 1999 May; 16(5):676-81. PubMed ID: 10350010 [TBL] [Abstract][Full Text] [Related]
15. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. Kazzaz J; Singh M; Ugozzoli M; Chesko J; Soenawan E; O'Hagan DT J Control Release; 2006 Feb; 110(3):566-73. PubMed ID: 16360956 [TBL] [Abstract][Full Text] [Related]
16. PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. Delgado A; Lavelle EC; Hartshorne M; Davis SS Vaccine; 1999 Jul; 17(22):2927-38. PubMed ID: 10438065 [TBL] [Abstract][Full Text] [Related]
17. Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines. Coombes AG; Major D; Wood JM; Hockley DJ; Minor PD; Davis SS Biomaterials; 1998 Jun; 19(11-12):1073-81. PubMed ID: 9692806 [TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of melittin-loaded poly (DL-lactic acid) or poly (DL-lactic-co-glycolic acid) microspheres made by the double emulsion method. Cui F; Cun D; Tao A; Yang M; Shi K; Zhao M; Guan Y J Control Release; 2005 Oct; 107(2):310-9. PubMed ID: 16255081 [TBL] [Abstract][Full Text] [Related]
19. Improving protein delivery from microparticles using blends of poly(DL lactide co-glycolide) and poly(ethylene oxide)-poly(propylene oxide) copolymers. Yeh MK; Davis SS; Coombes AG Pharm Res; 1996 Nov; 13(11):1693-8. PubMed ID: 8956336 [TBL] [Abstract][Full Text] [Related]
20. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. Perez C; Sanchez A; Putnam D; Ting D; Langer R; Alonso MJ J Control Release; 2001 Jul; 75(1-2):211-24. PubMed ID: 11451511 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]